tbuckley/cabot-search huggingface dataset:
Immune Responses of Healthy Humans 83–104 Years of Age&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: R Dworsky, A Paganini-Hill, M Arthur, J Parker
Journal: JNCI Journal of the National Cancer Institute (1983)

The immune responses of 19 healthy people 83-104 years of age were compared to those of younger healthy persons. A decline in mitogen response to concanavalin A and pokeweed mitogen, but not to phytohemagglutinin, was observed. Positive skin test to two recall antigens occurred in only 5 of the 19 aged people; 4 of these 5 reported a history of blood transfusion. Antibody titers were elevated for persistent DNA viruses but not for RNA viruses. An excess of ABO blood type B was found, but no human leukocyte antigen (HLA)-A or HLA-B type was found in elevated proportion.
Inhibition of Osteoarthritis by Adipose‐Derived Stromal Cells Overexpressing Fra‐1 in Mice
Authors: Kay Schwabe, Mireia Garcia, Kenia Ubieta, Nicole Hannemann, Bettina Herbort, Julia Luther, Daniele Noël, Christian Jorgensen, Louis Casteilla, Jean‐Pierre David, Michael Stock, Martin Herrmann, Georg Schett, Aline Bozec
Journal: Arthritis & Rheumatology (2015)

Objective To determine whether overexpression of the activator protein 1 (AP‐1) transcription factor Fra‐1 in adipose‐derived stromal cells (ADSCs) is an effective treatment of collagenase‐induced osteoarthritis (OA). Methods OA was induced by injection of collagenase into the knee joints of male C57BL/6 mice. ADSCs were isolated from the inguinal fat pads of 8‐week‐old wild‐type or Fra‐1–transgenic mice and injected into the knee joints of mice with collagenase‐induced OA 7 days after OA induction. Histologic analyses of cartilage destruction and chondrocyte cell death were performed. Adipogenic differentiation capacity was evaluated, gene expression was analyzed, and cytokine profiling was performed in stromal vascular fractions (SVFs) and ADSCs. Results OA‐related cartilage destruction and chondrocyte cell death were significantly reduced in mouse knee joints treated with ADSCs from Fra‐1–transgenic mice compared to mouse knee joints treated with ADSCs from wild‐type mice. This effect did not result from the higher number of adipogenic progenitors observed in SVFs from Fra‐1–transgenic compared to wild‐type mouse fat pads, since injection of wild‐type mouse ADSCs enriched for adipogenic progenitors did not show any additional chondroprotective effects compared to nonsorted ADSCs. However, Fra‐1–transgenic mouse ADSCs showed decreased adipogenic differentiation capacity. Moreover, Fra‐1 significantly inhibited proinflammatory interleukin‐6 and pentraxin 3 expression, while increasing the expression of extracellular matrix proteins, such as periostin and spondin 1. These findings suggest that Fra‐1 overexpression leads to an increased chondroprotective effect of ADSCs in OA. Conclusion ADSCs overexpressing Fra‐1 effectively protect against OA. Our data indicate that genetic modifications of ADSCs, such as Fra‐1 overexpression, may improve their potential to protect articular cartilage against OA‐mediated damage.
Medical implications of technical accuracy in genome sequencing
Authors: Rachel L. Goldfeder, James R. Priest, Justin M. Zook, Megan E. Grove, Daryl Waggott, Matthew T. Wheeler, Marc Salit, Euan A. Ashley
Journal: Genome Medicine (2016)

As whole exome sequencing (WES) and whole genome sequencing (WGS) transition from research tools to clinical diagnostic tests, it is increasingly critical for sequencing methods and analysis pipelines to be technically accurate. The Genome in a Bottle Consortium has recently published a set of benchmark SNV, indel, and homozygous reference genotypes for the pilot whole genome NIST Reference Material based on the NA12878 genome. We examine the relationship between human genome complexity and genes/variants reported to be associated with human disease. Specifically, we map regions of medical relevance to benchmark regions of high or low confidence. We use benchmark data to assess the sensitivity and positive predictive value of two representative sequencing pipelines for specific classes of variation. We observe that the accuracy of a variant call depends on the genomic region, variant type, and read depth, and varies by analytical pipeline. We find that most false negative WGS calls result from filtering while most false negative WES variants relate to poor coverage. We find that only 74.6 % of the exonic bases in ClinVar and OMIM genes and 82.1 % of the exonic bases in ACMG-reportable genes are found in high-confidence regions. Only 990 genes in the genome are found entirely within high-confidence regions while 593 of 3,300 ClinVar/OMIM genes have less than 50 % of their total exonic base pairs in high-confidence regions. We find greater than 77 % of the pathogenic or likely pathogenic SNVs currently in ClinVar fall within high-confidence regions. We identify sites that are prone to sequencing errors, including thousands present in publicly available variant databases. Finally, we examine the clinical impact of mandatory reporting of secondary findings, highlighting a false positive variant found in BRCA2. Together, these data illustrate the importance of appropriate use and continued improvement of technical benchmarks to ensure accurate and judicious interpretation of next-generation DNA sequencing results in the clinical setting.
Safety and Early Efficacy in an Ongoing Pilot Study of Brentuximab Vedotin and AVD Chemotherapy Followed By 30 Gray Involved-Site Radiotherapy for Newly Diagnosed, Early Stage, Unfavorable Risk Hodgkin Lymphoma
Authors: Anita Kumar, Joachim Yahalom, Heiko Schoder, Philip Caron, Pamela Drullinsky, John F. Gerecitano, Audrey Hamilton, Paul Hamlin, Steven M. Horwitz, Alexandra G. Jacob, Matthew J. Matasar, Susan McCall, Alison J Moskowitz, Ariela Noy, Lia Palomba, Carol S Portlock, David J. Straus, Stephanie Verwys, Andrew D. Zelenetz, Zhigang Zhang, Anas Younes, Craig H. Moskowitz
Journal: Blood (2014)
Better Health Care
Authors: David Blumenthal
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A Phase Ib Dose-Escalation Study of the Hsp90 Inhibitor Snx-5422 and Erlotinib in Patients with Egfr-Mutant Lung Cancer and Acquired Resistance to Egfr Tyrosine Kinase Inhibitors
Authors: H.A. Yu, M. Gutierrez, G.J. Riely, D. Graham, N. Busby, J. Hinson, E. Orlemons
Journal: Annals of Oncology (2014)
Expression Of Truncated Protein Tyrosine Phosphatase, Receptor Type, O (PTPROt) Influences Multiple Myeloma Sensitivity To Bortezomib Through Akt Signaling, and Is a Favorable Clinical Prognostic Factor
Authors: Hua Wang, Veerabhadran Baladandayuthapani, Zhiqiang Wang, Jiexin Zhang, Heather Yan Lin, Richard E. Davis, Lin Yang, Robert Z. Orlowski
Journal: Blood (2013)
Robust Estimation of Evolutionary Distances with Information Theory
Authors: Minh Duc Cao, Lloyd Allison, Trevor I. Dix, Mikael Bodén
Journal: Molecular Biology and Evolution (2016)

Methods for measuring genetic distances in phylogenetics are known to be sensitive to the evolutionary model assumed. However, there is a lack of established methodology to accommodate the trade-off between incorporating sufficient biological reality and avoiding model overfitting. In addition, as traditional methods measure distances based on the observed number of substitutions, their tend to underestimate distances between diverged sequences due to backward and parallel substitutions. Various techniques were proposed to correct this, but they lack the robustness against sequences that are distantly related and of unequal base frequencies. In this article, we present a novel genetic distance estimate based on information theory that overcomes the above two hurdles. Instead of examining the observed number of substitutions, this method estimates genetic distances using Shannon's mutual information. This naturally provides an effective framework for balancing model complexity and goodness of fit. Our distance estimate is shown to be approximately linear to elapsed time and hence is less sensitive to the divergence of sequence data and compositional biased sequences. Using extensive simulation data, we show that our method 1) consistently reconstructs more accurate phylogeny topologies than existing methods, 2) is robust in extreme conditions such as diverged phylogenies, unequal base frequencies data, and heterogeneous mutation patterns, and 3) scales well with large phylogenies.
Normalization of coronary flow reserve after coronary stenting and alpha-adrenergic antagonists
Authors: L. Gregorini, J. Marco, Carlo Palombo, I. Bossi, M. Kozàkovà, F. Donatelli, S. Romano, I. Marco, M. Bernies, C. Jordan, J. Fajadet, G: Heusch
Journal: Journal of the American College of Cardiology (2000)
Angiogenesis in Liquid Tumors: An In Vitro Assay for Leukemic‐Cell‐Induced Bone Marrow Angiogenesis
Authors: Yi Zheng, Yubing Sun, Xinwei Yu, Yue Shao, Ping Zhang, Guohao Dai, Jianping Fu
Journal: Advanced Healthcare Materials (2016)

The critical role of angiogenesis for solid tumor growth and metastatic spread has been well established. In contrast, even though increased vascularity has been commonly observed in bone marrows of patients with hematological malignancies (liquid tumors), the pathophysiology of leukemia-induced angiogenesis in the bone marrow remains elusive. This paper demonstrates the usage of a microengineered 3D biomimetic model to study leukemic-cell-induced bone marrow angiogenesis. Rational design of the 3D angiogenesis chip incorporating endothelial cells (ECs), leukemic cells, and bone marrow stromal fibroblasts provide an efficient biomimetic means to promote and visualize early angiogenic processes. Morphological features of angiogenesis induced by three different leukemic cell lines (U937, HL60, and K562) are investigated and compared. Quantitative measurements of angiogenic factors secreted from monocultures and cocultures of leukemic cells with bone marrow stromal fibroblasts suggest a synergistic relationship between ECs, leukemic cells, and bone marrow stromal fibroblasts for angiogenic induction, and also confirm the necessity of conducting functional angiogenic assays in proper 3D biomimetic cell culture systems like the one developed in this work.
Impact of the 2009 influenza A(H1N1) pandemic wave on the pattern of hibernal respiratory virus epidemics, France, 2009
Authors: J S Casalegno, M Ottmann, M Bouscambert-Duchamp, M Valette, F Morfin, B Lina
Journal: Eurosurveillance (2010)

This short report based on clinical surveillance and laboratory data describes the circulation of rhinoviruses, influenza viruses and respiratory syncytial viruses (RSV) in France during the 2009-10 season compared with the previous winter season. The delayed circulation of RSV observed in 2009-10 compared with 2008-09 suggests that the early circulation of the 2009 pandemic influenza A(H1N1) viruses had an impact on the RSV epidemic.
Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing
Authors: Alexa B. Schrock, Garrett M. Frampton, Dana Herndon, Joel R. Greenbowe, Kai Wang, Doron Lipson, Roman Yelensky, Zachary R. Chalmers, Juliann Chmielecki, Julia A. Elvin, Mira Wollner, Addie Dvir, Lior Soussan -Gutman, Rodolfo Bordoni, Nir Peled, Fadi Braiteh, Luis Raez, Rachel Erlich, Sai-Hong Ignatius Ou, Mohamed Mohamed, Jeffrey S. Ross, Philip J. Stephens, Siraj M. Ali, Vincent A. Miller
Journal: Clinical Cancer Research (2016)

Reliable detection of drug-sensitive activating EGFR mutations is critical in the care of advanced non-small cell lung cancer (NSCLC), but such testing is commonly performed using a wide variety of platforms, many of which lack rigorous analytic validation.A large pool of NSCLC cases was assayed with well-validated, hybrid capture-based comprehensive genomic profiling (CGP) at the request of the individual treating physicians in the course of clinical care for the purpose of making therapy decisions. From these, 400 cases harboring EGFR exon 19 deletions (Δex19) were identified, and available clinical history was reviewed.Pathology reports were available for 250 consecutive cases with classical EGFR Δex19 (amino acids 743-754) and were reviewed to assess previous non-hybrid capture-based EGFR testing. Twelve of 71 (17%) cases with EGFR testing results available were negative by previous testing, including 8 of 46 (17%) cases for which the same biopsy was analyzed. Independently, five of six (83%) cases harboring C-helical EGFR Δex19 were previously negative. In a subset of these patients with available clinical outcome information, robust benefit from treatment with EGFR inhibitors was observed.CGP identifies drug-sensitive EGFR Δex19 in NSCLC cases that have undergone prior EGFR testing and returned negative results. Given the proven benefit in progression-free survival conferred by EGFR tyrosine kinase inhibitors in patients with these alterations, CGP should be considered in the initial presentation of advanced NSCLC and when previous testing for EGFR mutations or other driver alterations is negative. Clin Cancer Res; 22(13); 3281-5. ©2016 AACR.
ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer
Authors: Shuai Gao, Huihui Ye, Sean Gerrin, Hongyun Wang, Ankur Sharma, Sen Chen, Akash Patnaik, Adam G. Sowalsky, Olga Voznesensky, Wanting Han, Ziyang Yu, Elahe A. Mostaghel, Peter S. Nelson, Mary-Ellen Taplin, Steven P. Balk, Changmeng Cai
Journal: Clinical Cancer Research (2016)

Abstract Purpose: ErbB2 signaling appears to be increased and may enhance androgen receptor (AR) activity in a subset of patients with castration-resistant prostate cancer (CRPC), but agents targeting ErbB2 have not been effective. This study was undertaken to assess ErbB2 activity in abiraterone-resistant prostate cancer and to determine whether it may contribute to AR signaling in these tumors. Experimental Design: AR activity and ErbB2 signaling were examined in the radical prostatectomy specimens from a neoadjuvant clinical trial of leuprolide plus abiraterone and in the specimens from abiraterone-resistant CRPC xenograft models. The effect of ErbB2 signaling on AR activity was determined in two CRPC cell lines. Moreover, the effect of combination treatment with abiraterone and an ErbB2 inhibitor was assessed in a CRPC xenograft model. Results: We found that ErbB2 signaling was elevated in residual tumor following abiraterone treatment in a subset of patients and was associated with higher nuclear AR expression. In xenograft models, we similarly demonstrated that ErbB2 signaling was increased and associated with AR reactivation in abiraterone-resistant tumors. Mechanistically, we show that ErbB2 signaling and subsequent activation of the PI3K/AKT signaling stabilizes AR protein. Furthermore, concomitantly treating CRPC cells with abiraterone and an ErbB2 inhibitor, lapatinib, blocked AR reactivation and suppressed tumor progression. Conclusions: ErbB2 signaling is elevated in a subset of patients with abiraterone-resistant prostate cancer and stabilizes AR protein. Combination therapy with abiraterone and ErbB2 antagonists may be effective for treating the subset of CRPC with elevated ErbB2 activity. Clin Cancer Res; 22(14); 3672–82. ©2016 AACR.
Bone marrow transplantation for Hodgkin's disease.
Authors: J A Russell, J Berry, W B Blahey, P H Geggie, B Houwen, A R Jones, M C Poon, B A Ruether
Journal: Journal of Clinical Oncology (1986)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1986.4.4.610 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3514809 Bone marrow transplantation for Hodgkin's disease. J A RussellxJ A RussellSearch for articles by this author , J BerryxJ BerrySearch for articles by this author , W B BlaheyxW B BlaheySearch for articles by this author , P H GeggiexP H GeggieSearch for articles by this author , B HouwenxB HouwenSearch for articles by this author , A R JonesxA R JonesSearch for articles by this author , M C PoonxM C PoonSearch for articles by this author , B A RuetherxB A RuetherSearch for articles by this author Show More https://doi.org/10.1200/JCO.1986.4.4.610 PDF "Bone marrow transplantation for Hodgkin's disease.." Journal of Clinical Oncology, 4(4), pp. 610–611© 1986 by American Society of Clinical Oncology
Expression of Heterophil Forssman Antigen on Cultured Malignant Cell Lines&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: T Mori, T Sudo, K Kano
Journal: JNCI Journal of the National Cancer Institute (1983)

By means of indirect immunofluorescence (IIF) tests with rabbit antiserum against Forssman (F) antigen, F-antigen was demonstrated on 5 of 7 cultured cell lines originating from various cancer tissues. Results of cytotoxicity tests with normal human sera with F-antibodies confirmed the presence of F-antigen on these "IIF-positive" cell lines. In contrast, F-antigen could not be detected under the same experimental conditions on B-cell lines established from lymphoma or leukemia patients or on lymphoblastoid cell lines established from normal individuals. The expression of F-antigen was also studied on transformed rat cell lines derived from an F-negative normal cell line, 3y1. Transformation of the 3y1 line by whole DNA or by the EcoRI-C fragment (0-16 map unit) but not by the Accl-H fragment (0-4.7 map unit) of adenovirus type 12 resulted in expression of F-antigen on the cell surface. The transformed cells with F-antigen showed an in vitro growth pattern characteristic of that seen in malignant cells; this observation indicates that F-antigen expression is closely associated with malignant transformation of the cells.
DNA Methyltransferase Activity Assays: Advances and Challenges
Authors: Wan Jun Poh, Cayden Pang Pee Wee, Zhiqiang Gao
Journal: Theranostics (2016)

DNA methyltransferases (MTases), a family of enzymes that catalyse the methylation of DNA, have a profound effect on gene regulation.A large body of evidence has indicated that DNA MTase is potentially a predictive biomarker closely associated with genetic disorders and genetic diseases like cancer.Given the attention bestowed onto DNA MTases in molecular biology and medicine, highly sensitive detection of DNA MTase activity is essential in determining gene regulation, epigenetic modification, clinical diagnosis and therapeutics.Conventional techniques such as isotope labelling are effective, but they often require laborious sample preparation, isotope labelling, sophisticated equipment and large amounts of DNA, rendering them unsuitable for uses at point-of-care.Simple, portable, highly sensitive and low-cost assays are urgently needed for DNA MTase activity screening.In most recent technological advances, many alternative DNA MTase activity assays such as fluorescent, electrochemical, colorimetric and chemiluminescent assays have been proposed.In addition, many of them are coupled with nanomaterials and/or enzymes to significantly enhance their sensitivity.Herein we review the progress in the development of DNA MTase activity assays with an emphasis on assay mechanism and performance with some discussion on challenges and perspectives.It is hoped that this article will provide a broad coverage of DNA MTase activity assays and their latest developments and open new perspectives toward the development of DNA MTase activity assays with much improved performance for uses in molecular biology and clinical practice.
Prevention for Hand-Foot Skin Reaction with Regorafenib Monotherapy for Refractory Metastatic Colorectal Cancer
Authors: Yumiko Ohta, Shuntaro Yoshida, Hideki Fujita, Akiko Narita, Takayuki Shimpou, Atsuo Yamada, Yoshinari Asaoka, Yoshihiro Hirata, Yutaka Yamaji, Kazuhiko Koike
Journal: Annals of Oncology (2014)
Intrauterine devices and intrauterine systems
Journal: Human Reproduction Update (2008)

From a public health viewpoint, the intrauterine device (IUD) is the most widely used contraceptive method in the world. Prevalence rates range among countries from 2 to 80% of contraceptive users. During 5 years of IUD use, pregnancy occurs in less than 2 per 100 insertions. Bleeding and pain are the most common reasons for removal rates of 10% in the first year and up to 50% within 5 years. The contraceptive effects of IUDs may be due to a sterile inflammatory reaction in the endometrial cavity which interferes with sperm function, so that fertilization is less likely to occur. IUDs also interfere with implantation but the extent to which this contributes to their contraceptive action is unknown. In nulliparous women rates of expulsion and removal for bleeding and/or pain are higher than in parous women. Effective use of IUDs for up to 10 years has the same pregnancy rate as tubal interruption. Thus, the IUD may be an alternative to female sterilization, especially in younger women who are more likely to experience regret after sterilization. The levonorgestrel intrauterine system (LNG-IUS) reduces bleeding and dysmenorrhoea, provides superior effectiveness to copper IUDs, and may be a useful treatment for endometriosis or an alternative to hysterectomy for menorrhagia.
Beyond antigens and adjuvants: formulating future vaccines
Authors: Tyson J. Moyer, Andrew C. Zmolek, Darrell J. Irvine
Journal: Journal of Clinical Investigation (2016)

The need to optimize vaccine potency while minimizing toxicity in healthy recipients has motivated studies of the formulation of vaccines to control how, when, and where antigens and adjuvants encounter immune cells and other cells/tissues following administration. An effective subunit vaccine must traffic to lymph nodes (LNs), activate both the innate and adaptive arms of the immune system, and persist for a sufficient time to promote a mature immune response. Here, we review approaches to tailor these three aspects of vaccine function through optimized formulations. Traditional vaccine adjuvants activate innate immune cells, promote cell-mediated transport of antigen to lymphoid tissues, and promote antigen retention in LNs. Recent studies using nanoparticles and other lymphatic-targeting strategies suggest that direct targeting of antigens and adjuvant compounds to LNs can also enhance vaccine potency without sacrificing safety. The use of formulations to regulate biodistribution and promote antigen and inflammatory cue co-uptake in immune cells may be important for next-generation molecular adjuvants. Finally, strategies to program vaccine kinetics through novel formulation and delivery strategies provide another means to enhance immune responses independent of the choice of adjuvant. These technologies offer the prospect of enhanced efficacy while maintaining high safety profiles necessary for successful vaccines.